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1. Introduction 
Paclitaxel, administered as intravenous infusion currently, is an effective anticancer drug 
belonging to the taxane family (Figure 1) and used in the treatment of a wide variety of 
cancers including breast and ovarian cancers (Rowinsky et al., 1995). Researchers have been 
looking for more effective and convenient ways to administer paclitaxel with less 
formulation-related toxicities than the commercially available formulations like Taxol® by 
Bristol-Meyers Squibb. It is well known that some of the limitations of the current 
formulation come from Cremophor EL, a polyoxyethylated castor oil. This particular 
component is known to cause hypersensitivity (Weiss et al., 1990), to be responsible for 
nonlinear pharmacokinetic behavior (Kearns et al., 1995; Gianni, 1995) and to cause 
paclitaxel precipitation oftentimes when diluted during the infusion process (Pfeifer, 1993). 
Formulations for paclitaxel and its analogs have been prepared in many different ways for 
various administration procedures (Kim et al., 2006; Xie et al., 2007; Sugahara et al., 2007; 
Singla et al., 2002; Hennenfent & Govindan, 2006). Several years ago, Abraxane®, a 
suspension of albumin nanoparticles containing paclitaxel, obtained approval to treat 
metastatic breast cancer patients (Ibrahim et al., 2002; Garber, 2004). Abraxane®, a solvent- 
 
Fig. 1. Structure of paclitaxel 
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Formulation AUC 
(μg·h/ml) 
Cmax 
(μg/ml) 
Dose 
(mg/kg) 
Rodent 
species 
Ref 
Without inhibitors 
Taxol 0.50 (0-8*) 0.14 10 mice Sparreboom et al., 1997 
Taxol 0.37 (0-4) 0.13*** 10 mice Bardelmeijer et al., 2004 
Taxol 1.89 (0-∞) 0.11 50 rat Choi & Li, 2005 
Taxol 0.41 (0-6) 0.12 10 mice Bardelmeijer et al., 2000 
Cremophor/ethanol 0.51 (0-24) 0.10 5 mice Asperen et al., 1998 
Supersaturable-SEDDS 0.44 (0-∞) 0.28 10 rat Gao et al., 2003 
SMEDDS 0.81 (0-24) 0.05 2 rat Yang et al., 2004 
SMEDDS 0.97 (0-24) 0.05 10 rat Yang et al., 2004 
microemulsion 0.45 (0-24) 0.05 25 rat Woo et al., 2003 
Suspension in Tween 80 1.65 (0-24) 0.11 40 rat Choi et al., 2004a, 2004b 
Lipid nanocapsule 1.05 (0-∞) 0.37 10 rat Peltier et al., 2006 
With inhibitors 
Cremophor/Ethanol 
+Cyclosporine A (50**) 
6.68 (0-24) 0.73 10 mice Asperen et al., 1998 
Supersaturable-SEDDS 
+cyclosporine A (30) 
1.05 (0-∞) 0.31 10 rat Gao et al., 2003 
SMEDDS+cyclosporine A (40) 1.14 (0-24) 0.16 2 rat Yang et al., 2004 
Taxol+verapamil (15) 4.27 (0-∞) 0.19 50 rat Choi & Li, 2005 
Microemulsion+KR-30031 (20) 3.37 (0-24) 0.22 25 rat Woo et al., 2003 
Surfactant mix + KR30031 (5) 0.39 (0-12) 0.06 5 rat Kim et al., 2004 
Suspension in Tween 80 + 
quercetin (20) 
5.00 (0-24) 0.28 40 rat Choi et al., 2004b 
Taxol+cyclosporine A (50) 3.61 (0-4) 0.82*** 10 mice Bardelmeijer et al., 2004 
Taxol+PSC 833 (50) 2.71 (0-4) 1.47*** 10 mice Bardelmeijer et al., 2004 
Taxol+GF120918 (25) 1.39 (0-4) 0.55*** 10 mice Bardelmeijer et al., 2004 
Taxol+LY335979 (80) 1.41 (0-4) 0.42*** 10 mice Bardelmeijer et al., 2004 
Taxol+R101933 (80) 0.93 (0-4) 0.32*** 10 mice Bardelmeijer et al., 2004 
Taxol+GF120918 (25) 2.65 (0-10) 0.77 10 mice Bardelmeijer et al., 2000 
Taxol+PSC 833 (50)    mice Asperen et al., 1997 
* Time-interval used for the calibration of AUC, 
** Dose of the inhibitor in mg/kg, and 
*** Estimated concentration 
Table 1. Mini-review: Selective pharmacokinetic data of paclitaxel after oral administration 
to rodents.  
free formulation has a number of improved features such as shorter infusion time and no 
hypersensitivity without premedication (Garber, 2004). 
Since an oral route would clearly be an attractive alternative to injection for patients as well 
as for medical personnel, there have been many attempts to prepare effective oral paclitaxel 
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formulations. Paclitaxel, however, is known to be absorbed poorly in the gastrointestinal 
tract when administered orally (Sparreboom et al., 1997; Bardelmeijer et al., 2004; Choi & Li, 
2005; Bardelmeijer et al., 2000). The reasons for poor absorption were identified to be drug 
metabolism by cytochrome P450 (CYP) and the existence of the efflux system, such as P-
glycoproteins in intestinal epithelial cells and liver (Schellens et al., 2000). Tellingen and co-
workers identified that the epithelial efflux system composed of P-glycoproteins lowered 
the drug absorption by demonstrating that orally administered paclitaxel can be absorbed 
well in mice with a homozygously disrupted mdr1a gene (mdr1a(-/-) mice) (Sparreboom et 
al., 1997). Proof-of-concept experiments in mice and man have also shown that oral 
absorption of paclitaxel could be increased dramatically by concomitant administration of a 
P-glycoprotein inhibitor, cyclosporine A (Schellens et al., 2000; Asperen et al., 1998; Meerum 
Terwogt et al., 1999). Other P-glycoprotein blockers that could also serve as CYP 450 
inhibitors also boosted the oral absorption of paclitaxel (Sparreboom et al., 1997; 
Bardelmeijer et al., 2004; Choi & Li, 2005; Kim et al., 2004; Asperen et al., 1997). Formulations 
that do not contain Cremophor EL, that could lower the in vivo toxicity and increase 
solubilization of paclitaxel, were shown to deliver paclitaxel efficiently via oral 
administration especially when P-glycoprotein inhibitors were given simultaneously (Kim 
et al., 2004; Gao et al., 2003; Yang et al., 2004; Woo et al., 2003; Choi et al., 2004a, 2004b; 
Peltier et al., 2006).  
In Table 1, we reviewed the literature on oral paclitaxel formulations and summarized the 
pharmacokinetic data of paclitaxel obtained from the small-animal experiments (FVB mice 
and Sprague-Dawley rats). In the Table, we have listed Area under the plasma concentration 
vs. time curve (AUC) value, maximum drug concentration in the blood (Cmax) and oral dose. 
One has to keep in mind that the data from different papers may not be compared directly 
since the AUC values in the literature were estimated for different time intervals and drug 
doses while the pharmacokinetics of paclitaxel is known to be non-linear (Kearns et al., 1995; 
Gianni, 1995). Different time intervals could not be normalized due to lack of information in 
the pharmacokinetics data to make such estimations and thus must be viewed with caution. 
Another important point to note is that Cremophor EL in Taxol®, used for intravenous 
administration in some cases (Sparreboom et al., 1997; Bardelmeijer et al., 2004; Asperen et 
al., 1998; Gao et al., 2003; Yang et al., 2004; Peltier et al., 2006), causes nonlinear 
pharmacokinetic behavior (Sparreboom et al., 1996). Also, paclitaxel dissolved in Tween 80, 
also used for intravenous controls in others (Choi & Li, 2005; Bardelmeijer et al., 2000; Woo 
et al., 2003; Choi et al., 2004a, 2004b), does show linear pharmacokinetic behavior, but has ca. 
5~10 times lower AUC values when compared to diluted Taxol® (Sparreboom et al., 1996). 
For these reasons, it was impossible to list the bioavailability values in Table 1. 
In the past several years, we have been developing paclitaxel formulations with 
biocompatible oils, lipids and emulsifiers (Lee et al. Hong et al., 2004; I. H. Lee et al., 2005; S. 
J. Lee et al., 2005). Paclitaxel dissolved in a stable Lipiodol formulation was shown to retard 
the growth of hepatocellular carcinoma efficiently when transcatheter arterial 
chemoembolization was performed in rabbits (Yoon et al., 2003). Also, a paclitaxel 
formulation prepared with monoolein, tricaprylin and Tween 80 was mucoadhesive when 
given intravesically (S. J. Lee et al., 2005). Paclitaxel in this formulation penetrated to lamina 
propria and close to the muscle layer of the bladder while the paclitaxel concentration was 
low throughout the depth of the bladder tissue when Taxol® was used. We also have shown 
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that this mucoadhesive formulation can deliver paclitaxel effectively when given by oral 
route without additional active pharmaceutical ingredient as an absorption enhancer (Lee et 
al., 2004; Hong et al., 2004; I. H. Lee et al., 2005, Shin et al., 2009). As an endeavor to 
formulate more efficient oral paclitaxel formulations, we have prepared oil-based paclitaxel 
formulations with monoolein, saturated triglycerides and emulsifiers. Monoolein was 
included in the formulation as a main ingredient due to its high bioadhesiveness (Nielsen et 
al., 1998) and its ability to release the encapsulated drug in a controlled fashion (Clogston et 
al., 2005a, 2005b). Triglycerides were added since they can solubilize paclitaxel efficiently 
(Kan et al., 1999). To access the effectiveness of the formulations, pharmacokinetic and anti-
tumor efficacy studies were performed in mice models. 
2. Materials and methods 
2.1 Materials 
Distilled monoolein (RYLOTM MG 19, > 90 % pure) was purchased from Danisco 
Ingredients, Denmark. Paclitaxel was obtained from Samyang Genex (Korea) and Indena 
S.P.A. (Italy). Cremophor EL, Tween 80 and triglycerides (triacetin, tributyrin, tricaproin, 
tricaprylin, tricaprin and trilaurin) were purchased from Sigma Chemical Co. (St. Louis, 
MO).  
2.2 Preparation of oral paclitaxel formulations 
The compositions of the oral paclitaxel formulations used in the experiments are 
summarized in Tables 2 and 3. Paclitaxel formulations with various triglycerides (Table 2) 
were prepared as follows: Paclitaxel in amorphous form was dissolved completely at 10 
mg/ml in mixtures of oils consisting of monoolein, triglycerides and Tween 80 by sonication 
for 30 s. Some of the oral paclitaxel formulations were semi-solid or solid wax at ambient 
temperatures with the melting points of 30 ~ 50 ˚C, and therefore had to be warmed before 
oral feeding. 
In Table 3, Paclitaxel, amorphous or crystalline, was dissolved completely in excess amount 
of methylene chloride and mixed subsequently with tricaprylin. Methylene chloride was 
evaporated completely to prepare paclitaxel/tricaprylin solution by vacuum evaporation 
(BUCHI rotavapor R-200, Germany) at 40 ˚C for 1 h. The content of methylene chloride was 
determined by gas chromatography and was less than 100 ppm in the paclitaxel/tricaprylin 
solution. Monoolein and Tween 80 were added to the paclitaxel/tricaprylin solution and 
mixed completely by sonication for 30 s. A formulation that does not contain paclitaxel, eG2, 
was also prepared for control. The oral paclitaxel formulations were semi-solid wax with the 
melting temperature of 33 ~ 35 ˚C, and were warmed to body temperature before feeding. 
Dispersions of the oral paclitaxel formulations (G8, G9, and G10) were prepared by adding 
2.3 times (by volume) of distilled water or syrup to the formulation G2 (also will be referred 
to as DHP107) and by vortexing or sonicating for 1 min.  
2.3 Animals 
Male ICR and Balb/c athymic mice, 7 weeks old, were purchased from Orient Bio Co. 
(Seoul, Korea) and Japan SLC (Japan), respectively, and maintained 1 week. Animal care 
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and handling followed institutional guidelines (Korea Institute of Science and 
Technology). Mice were maintained with free access to food and water under a 12-h 
light/dark cycle. 
2.4 Differential scanning calorimetry 
Differential scanning calorimetry (DSC) was performed to obtain the heating thermograms 
of paclitaxel and the formulations in Table 2 (DSC 821e, Mettler Toledo, Columbus, OH, 
equipped with Intracooler, Haake EK90/MT, Haake, Denmark) at a heating scan rate of 5 
˚C/min. Scans were made with samples contained in hermetically sealed aluminum 
crucibles (ME-27331, Mettler Toledo). Initial heating scans were reported for paclitaxel and 
the formulations in Table 2. In case of the formulations, thermal history did not alter the 
heating thermograms if the samples were cooled to – 20 ˚C before reheating.  
2.5 Determination of the particle size in the dispersion 
The average particle size in the dispersions G8, G9 and G10 in Table 3 was determined by 
quasielastic laser light scattering with a Malvern Zetasizer (Malvern Instruments Limited, 
England). The dispersions were diluted by 300 times in water before the measurement. The 
size determination was repeated 3 times/sample. The average size and the size distribution 
were estimated from the log-normal size distribution function as shown previously (Chung 
et al., 2001) 
2.6 Oral administration of paclitaxel formulations 
Paclitaxel formulations in Tables 2 and 3 were liquefied at 37 ~ 50 ˚C and administered 
orally at doses of 25, 50, 75, and 100 mg/kg with a blunt needle via the esophagus into the 
stomach. The male ICR mice were fasted for 8 h prior to oral administration except for the 
group G3. Taxol® prepared by dissolving paclitaxel in an equivolume mixture of Cremophor 
EL and ethanol at 6 mg/ml (Taxol®) was diluted by 6 times with the saline solution, and was 
administered via bolus tail-vein injection at a dose of 10 mg/kg as a positive control. Blood 
samples were collected at various time points (n=6) after drug administration, and were 
stored at -70 ˚C until analysis.  
2.7 Analysis of paclitaxel concentrations in blood 
Whole blood (200 μl) was spiked with irbesartan (0.5 μg/ml; internal standard), mixed and 
added to acetonitrile (400 μl) to precipitate proteins. After centrifugation at 14,000 RCF for 
20 min, the supernatant was collected and mixed with the mobile phase to adjust the 
volume to 0.6 ml. Ten microliters of the blood was injected into the LC/MS/MS system. 
Analyses were performed with a Thermo-Finnigan Discovery Max LC/MS/MS (San Jose, 
CA, USA). The LC system was performed at 35 ˚C on a Capcellpak C18 column (150 X 2.0 
mm i.d., 5 μm particle size, Shisheido, Japan) equipped with a Zorbax SB-Aq (12.5 X 2.1 mm 
i.d.) guard column. The mobile phase consisted of 55 % acetonitrile, 0.08 % formic acid and 
44.92 % water, and the flow rate was 0.4 ml/min. The instrument was operated in SRM 
mode (positive ion), monitoring the ion transitions from m/z 854  285 (paclitaxel) and 
m/z 429  195 (internal standard). The paclitaxel LC/MS/MS assay was linear over the 
range of 2 ~ 1000 ng/ml with a lower quantitation limit of 2 ng/ml in blood. Paclitaxel 
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concentrations in blood were calculated based on a standard curve of paclitaxel in blank 
pooled animal blood with the internal standard.  
2.8 Tumor experiment 
Suspension of NCI-H358 human non-small cell lung cancer cells (1.2×107 cells/mouse), 
purchased from American Type Culture Collection (ATCC, Manassas, VA), was injected 
subcutaneously to the dorsal flank of male Balb/c athymic mice (8 weeks). When the tumor 
volume (length × width × height × 0.5236) reached ca. 100 mm3 in 10 days after the injection 
(day 0), the experimental groups were divided at random into three groups (n=8). On days 
1, 2, 3, 4 and 5, G2 formulation (DHP107) was administered orally at a dose of 50 mg/kg 
(G2). For controls, mice injected intravenously with diluted Taxol® (Taxol, 10 mg/kg) and 
fed orally with the vehicle only (eG2) on days 1, 2, 3, 4 and 5 were also observed.  
2.9 Characterization of crystalline forms of paclitaxel 
X-Ray diffraction (XRD) measurements were made by using an x-ray diffractometer (D8 
Discover, Bruker, Karlsruhe, Germany) with the general area detector diffraction system 
(GADDS, Bruker, Karlsruhe, Germany). The Cu Kα radiation of wavelength 1.542 Å was 
provided by the x-ray generator (FL CU 4 KE, Bruker, Karlsruhe, Germany) operating at 40 
kV and 45 mA. Sample-to-detector distance was 300 mm. Exposure time was 1 ~ 5 h. To 
avoid air scattering, the beam path was filled with helium. The surface morphology of 
paclitaxel was observed by scanning electron microscopy (SEM; Hitachi S-2460N, Japan) at 
an accelerating voltage of 15 kV after Pt/Au sputter coating (Hitachi E1010 Ion sputter, 
Japan).  
3. Results 
3.1 Characterization of crystalline forms of paclitaxel 
Crystalline forms of paclitaxel obtained from different sources were determined by DSC, x-
ray diffraction and scanning electron microscopy. Paclitaxel can exist as different 
polymorphs having distinct physical properties, which could influence the manufacturing 
process of the formulations (Liggins et al., 1997; Lee et al., 2001). Paclitaxel obtained from 
Samyang Genex (Genexol, Korea) had the glass transition temperature at 150 ˚C and an 
exothermic transition at 220 ˚C whereas paclitaxel obtained from Indena had the melting 
transition at 210 ˚C as shown in Figure 2, corresponding to amorphous and anhydrous 
crystalline forms, respectively, as shown in the literature (Liggins et al., 1997). X-ray 
diffraction data revealed the differences in the crystallinity of paclitaxel. Diffraction pattern 
of Genexol showed two broad scattering peaks centered at ca. 10˚ and 20˚ characteristic of 
the amorphous form. Paclitaxel from Indena, on the other hand, revealed a pattern with 
strong and sharp diffraction peaks at 5.7˚ and 12.6˚ indicating a highly ordered structure. 
Surface morphology was also visualized by SEM. Genexol was observed to be in the powder 
form with highly contoured surfaces. We note that the grain size or the surface area of the 
powder varied depending on the lot numbers of Genexol (data not shown). For instance, 
Genexol 131 was composed of powders with wrinkled surfaces whereas Genexol 183 
contained smooth and round particles as well when observed by SEM. Needle-like crystals 
were observed for paclitaxel from Indena. Based on DSC, XRD and SEM experiments,  
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Fig. 2. Differential Scanning calorimetry, x-ray diffraction and scanning electron microscopy 
of paclitaxel obtained from of Genexol (upper panels) and Indena (lower panels).  
we confirmed that Paclitaxel from Samyang Genex and Indena were in amorphous and 
anhydrous crystalline forms, respectively.  
Due to the differences in the grain size and crystalline forms, we used two different 
procedures in preparing the oral formulations. Genexol 131 was readily soluble in all of the 
lipid mixtures in Table 2 when sonicated for ca. 30 s. Genexol 183, which had larger grains 
than Genexol 131, and paclitaxel from Indena did not dissolve in the lipid mixture. In these 
cases, paclitaxel was solubilized completely in the mixture of methylene chloride and 
triglyceride. Methylene chloride was evaporated completely from the mixture before other 
ingredients were added to prepare the formulations in Table 3.  
3.2 Physical properties of oral paclitaxel formulations 
Oral paclitaxel formulations existed as oil/wax mixtures at ambient temperatures, but 
formed clear liquid at 37 ˚C except for the Formulation T12 (Table 2). The T12 formulation 
existed as solid wax at ambient temperatures. Thermal behavior of the formulations 
containing different triglycerides was investigated by performing DSC (Figure 3A).  
The thermograms were identical with or without paclitaxel in the formulations, and those 
with paclitaxel are shown in the Figure. Tween 80, liquid at room temperature, did not show 
any phase transition in the temperature range from 0 to 60 ˚C. Lamellar crystalline-to-fluid 
isotropic, or the chain melting, phase transition of monoolein was observed at 32 ˚C, which 
is similar to the values reported for pure monoolein (Briggs et al., 1996; Qiu & Caffrey, 2000) 
or Myverol 18-99K (Clogston, 2000) in the literature. The chain melting transition of 
monoolein for the monoolein/Tween 80 (55.0:16.5 by weight) mixture was observed at 26 ˚C, 
since Tween 80 lowered the transition temperature of monoolein. In the formulations T2, T4 
and T6, only the chain melting transition of monoolein was observed because triacetin,  
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Fig. 3. A) Heating thermograms obtained from the formulations prepared with different 
triglycerides (T2 ~ T12, in Table 2), Tween 80, monoolein and monoolein/Tween 80 mixture 
(55.0:16.5 by weight). The concentration of paclitaxel was 1 %(w/w) in all formulations. B) 
Solubility of paclitaxel in the formulations containing monoolein, triglyceride and Tween 80 
at 55.0:27.5:16.5 by weight at 37 C.  
tributyrin and tricaprin were immiscible with solid monoolein. We could identify visually 
the phase separation of these triglycerides below ca. 26 ˚C. In T8 formulation, chain melting 
transitions of tricaprylin and monoolein were observed at 8 and 23 ˚C, respectively. In case 
of T10 formulation, single transition peak from the melting transition of the eutectic mixture 
of monoolein and tricaprin (2:1 by weight) was observed at 26 ˚C (Roh et al., 2004). The 
chain melting transitions of monoolein and trilaurin were observed at 32 and 41 ˚C, 
respectively, for T12 formulation. Results show that all the formulations existed as 
solid/liquid or solid/solid mixtures at room temperature, but transforms into the single-
phase liquid when heated to the body temperature for T2 ~ T10 formulations or above 45 ˚C 
for T12 formulation. Paclitaxel was solubilized well inside all of the formulations in the 
temperature range studied when observed by polarized light microscopy (data not shown).  
3.3 Solubility of paclitaxel in oral formulations 
The solubility of paclitaxel in the oral formulations with different triglycerides was 
determined at 37 ˚C. Mixtures of monoolein/triglyceride/Tween 80 were prepared at 
55.0:27.5:16.5 by weight and warmed to melt. Paclitaxel in powder form (Genexol, Samyang 
Genex, lot G131) was added stepwise to these mixtures until undissolved aggregates were 
observed. The mixtures were vortexed for 10 s and sonicated for 3 min after each addition at 
37 ˚C. The formulation containing trilaurin was heated to 60 ˚C and cooled to 37 ˚C to obtain 
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the undercooled liquid for the measurement. Solubility of paclitaxel was ca. 250 ± 30 mg/ml 
for the formulation containing triacetin, but was ca. 120 ± 40 mg/ml for those with other 
triglycerides (Figure 3B).  
3.4 Pharmacokinetics of oral paclitaxel administration and intravenous Taxol  
injection 
Oral paclitaxel formulations were warmed to body temperature and administered to male 
ICR mice. We note that not the dispersions but the oily formulations were administered, and 
no other active pharmaceutical ingredients were given to the animals. Diluted Taxol® was 
given intravenously as a control. Paclitaxel concentration in blood after oral administration 
of formulation G2 (DHP107, paclitaxel dose of 50 mg/kg) and intravenous injection of 
Taxol® (10 mg/kg) was plotted as a function of time in Figure 4A (normal scale) and Figure 
4B (logarithmic scale). Paclitaxel concentration in blood was 60.2 μg/ml in 1 min after 
intravenous injection, and dropped to ca. 6.2 and 0.8 μg/ml and in 0.5 and 3 h, respectively. 
Paclitaxel concentration in blood increased and became 1.2 and 2.1 μg/ml at 1 and 3 h, 
respectively, after oral administration of DHP107. Pharmacokinetic parameters are listed in 
Table 2. The bioavailability [(BA) (%) = (AUCoral / AUCiv) · (Doseiv/ Doseoral) ×100] of 
DHP107 in mice was ca. 14 %. Since the plasma concentration of paclitaxel above a threshold 
value of 85.3 ng/ml (dashed line in Figure 4B) was proven to be pharmacologically active, 
DHP107 could be effective for more than 8 h (Huizing et al., 1997).  
 
Treatment group Triglyceride type Tmax (h) Cmax (μg/ml) AUC0-9 (μg·h /ml) 
T2 Triacetin 3 0.4 1.6 
T4 Tributyrin 3 1.5 5.4 
T6 Tricaproin 3 3.1 12.0 
T8 Tricaprylin 1 2.7 8.9 
T10 Tricaprin 1 2.2 8.4 
T12 Trilaurin 1 1.5 4.9 
Table 2. Pharmacokinetic parameters of paclitaxel after oral administration (50 mg/kg dose) 
of the formulations containing different triglycerides to Balb/c mice. The composition of the 
formulations was paclitaxel:monoolein:triglyceride:Tween 80 = 1.0:55.0:27.5:16.5 by weight. 
3.5 Oral administration of formulations with different triglycerides 
Paclitaxel formulations prepared with various triglycerides (paclitaxel: monoolein: 
triglyceride:Tween 80 = 1.0:55.0:27.5:16.5 by weight) were administered orally at 50 mg/kg 
dose to male ICR mice (Table 2, Figure 4C). AUC values were 12.1 ± 2.6, 8.9 ± 1.8 and 8.4 ± 
2.7 μg·h/ml for T6, T8 and T10 groups, respectively, with no statistical differences (p<0.15 
by Student t-test). In case of T2, T4 and T12 groups, AUC of paclitaxel was 1.6 ± 0.5 (p<0.003 
compared the AUC with T6 formulation), 5.4 ± 0.7 (p<0.01) and 4.9 ±1.6 μg·h/ml (p<0.01), 
respectively. Maximum concentration of paclitaxel in blood (Cmax) was also the highest for 
the formulation with tricaproin (T6) and was 3.2 ± 0.7 μg·h/ml. Interestingly, the time to 
reach Cmax (Tmax) was 3 h for the formulations with shorter chain triglycerides (T2, T4 and 
T6) and 1 h for T8, T10 and T12 groups.  
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Fig. 4. Mean blood concentration of paclitaxel after intravenous administration of Taxol® 
and administration of oral formulations. Comparison between intravenous Taxol (⊞, 10 
mg/kg) and oral DHP107 (G2, , 50 mg/kg) is shown in normal (A) and logarithmic (B) 
scales. The dashed line in B) indicates the pharmacologically effective concentration (85.3 
ng/ml). Oral administration of paclitaxel formulations C) with different triglycerides (T2: , 
T4: , T6: , T8: , T10: , T12: ), D) with different paclitaxel contents (G1: , 5 mg 
paclitaxel/ml formulation, G2, DHP107: , 10 mg/ml, G3: , 15 mg/kg, G4: , 20 mg/ml), 
E) under the fasting (G2, DHP107: ) and non-fasting (G5: ) conditions, F) prepared with 
crystalline (G6: ) and amorphous (G2, DHP107: ) paclitaxel, G) with (G2, DHP107: ) or 
without (G7: ) Tween 80, and H) dispersed in syrup (G8: ) or in water (G9: ) by 
vortexing and in water by sonication (G10: ) or given per se (G2, DHP107: ). The oral 
dose of paclitaxel was 50 mg/kg except for G1 (25 mg/kg), G3 (75 mg/kg) and G4 (100 
mg/kg). 
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Treatment 
group 
Paclitaxel 
Dose 
(mg/kg) 
Composition [%(w/w)] 
Tmax 
(h) 
Cmax 
(μg/ml) 
AUC0-9 
(μg h 
/ml) 
Crystallinity 
of paclitaxel Paclitaxel Monoolein Tricaprylin Tween 
80 
Cremophor 
EL 
Ethanol 
G1 25 (p.o.) 0.5 55.5 27.5 16.5 - - 3 1.3 5.2 Amorphous 
G2 
(DHP107) 50 (p.o.) 1.0 55.0 27.5 16.5 - - 3 2.0 11.0 Amorphous 
G3 75 (p.o.) 1.5 54.5 27.5 16.5 - - 1 2.0 4.7 Amorphous 
G4 100 (p.o.) 2.0 54.0 27.5 16.5 - - 1 1.5 3.1 Amorphous 
G5 
(DHP107, 
Non-
fasting) 
50 (p.o.) 1.0 55.0 27.5 16.5 - - 1 3.4 15.3 Amorphous 
G6 50 (p.o.) 1.0 55.0 27.5 16.5 - - 3 1.6 8.3 Crystalline 
G7 50 (p.o.) 1.0 66.0 33.0 - - - 1 2.7 6.3 Amorphous 
eG2 0 (p.o.) 0.0 56.0 27.5 16.5 - - - - - - 
Taxol 10 (i.v.) 0.6 - - - 57.0 42.4 0.016 60.2 15.7 Amorphous 
Treatment 
group 
Paclitaxel 
Dose 
(mg/kg) 
Composition [%(w/w)] Tmax 
(h) 
Cmax 
(μg/ml) 
AUC0-9 
(μg h 
/ml) Dispersing 
method 
Paclitaxel Monoolein Tricaprylin Tween 80 Syrup Water    
G8 50 (p.o.) 0.3 16.2 8.0 5.5 70 - 3 1.2 4.6 Vortex 
G9 50 (p.o.) 0.3 16.2 8.0 5.5 - 70 3 1.8 7.5 Vortex 
G10 50 (p.o.) 0.3 16.2 8.0 5.5 - 70 1 1.6 7.1 Sonication 
Table 3. Compositions of paclitaxel formulations and pharmacokinetic parameters of 
paclitaxel after intravenous or oral administration in Balb/c mice.  
3.6 Oral administration of formulations with different paclitaxel contents 
We prepared the formulations with different Paclitaxel contents while fixing the weight 
ratio of monoolein:tricaprylin:Tween 80 to 55.0:27.5:16.5 by weight (G1, G2, G3 and G4 in 
Table 3, Figure 4D). Bioavailability was 13 % and 14 % when the concentration of paclitaxel 
was 0.5 and 1 %(w/w), respectively, in the formulation. When the concentration was 1.5 and 
2.0 %(w/w), bioavailability decreased with increasing paclitaxel dose and was 4 % and 2 %, 
respectively.  
3.7 Fasting vs. non-fasting conditions 
When the formulation is given orally, the fullness of stomach can influence the 
pharmacokinetics of the administered drug. Throughout the experiments, we administered 
the oral formulations after 8 h of fasting. In G5, however, we fed DHP107 to mice with free 
access to food and water before and after the drug administration in order to observe the 
influence of stomach emptiness on the absorption of the drug. Under the non-fasting 
condition, Cmax increased to 3.4 μg/ml when compared to the fasting condition (2.0 μg/ml) 
and Tmax was reduced to 1 h (Figure 4E). The AUC values for non-fasting and fasting 
conditions were 15.3 (20 % BA) and 11.0 μg·h /ml (14 % BA), respectively. We could 
conclude that the food in the gastrointestinal tract did not interfere with, but rather helped 
the absorption of paclitaxel.  
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3.8 Crystalline vs. amorphous paclitaxel 
The formulations made with crystalline and amorphous paclitaxel were administered orally to 
mice (Figure 4F). The pharmacokinetic profiles were virtually identical for these two 
formulations. We expected that the crystallinity of the drug would not affect the degree of oral 
absorption since paclitaxel was dissolved completely in tricaprylin/dichloromethane mixture 
before adding other ingredients, and therefore, the final products would be identical.  
3.9 Formulation without Tween 80 
Oral formulations with (G2, DHP107, Table 3) or without Tween 80 (G7) were prepared. 
Pharmacokinetic profiles were different for these two formulations (Figure 4G). When the 
formulation without Tween 80 was administered, Tmax was 1 h instead of 3, and the AUC 
value was reduced to 6.3 μg·h /ml, which was ca. 56 % of that for DHP107.  
3.10 Oral administration of the aqueous dispersions of DHP107 
Even though our oral paclitaxel formulations including DHP107 can be taken per se, they can 
also be mixed with water or taste-masking syrups for administration. To examine how the 
absorption of paclitaxel changes upon feeding the dispersion, DHP107 was mixed with 
water or syrup at 3:7 by weight. DHP107 was dispersed spontaneously in water to produce 
emulsion droplets having average diameter of 6-8 μm. By vortexing the mixture of DHP107 
and water or syrup for 1 min, the diameters of emulsion droplets were reduced to 6 
(polydispersity = 1) or 3 (polydispersity = 1) μm, respectively. By sonicating DHP107/water 
mixture at 180 KW for 1 min, we also obtained the dispersion with the oil droplets having 
1.4 μm (polydispersity = 1) in diameter. 
When the dispersions were orally administered, pharmacokinetic profiles did not change 
significantly except for the fact that the AUC values were reduced to ca. 40 ~ 70 % of the 
original G2 formulation.  
3.11 Antitumor efficacy of DHP107 in experimental animals 
To evaluate the antitumor activity of DHP107 in mice, suspension of NCI-H358 cells was 
injected subcutaneously to Balb/c athymic mice. All of the mice inoculated with the human 
non-small cell lung cancer cells developed progressively growing tumors. The mice were 
administered orally with DHP107 (G2, 50 mg/kg) or intravenously with Taxol® (10 mg/kg) for 
5 consecutive days 10 days after the inoculation. The entire tumor tissue was removed 
surgically after the experiment and photographed as shown in Figure 5A. In the group 
administered with oral DHP107 and intravenous Taxol®, the tumor size was reduced gradually 
from ca. 100 to 15 ± 3 and 19 ± 5 mm3, respectively, in ca. 25 days after the administration of the 
drug and remained unchanged for the duration of the experiment (Figure 5B). The tumor size 
data for these two groups were indifferent statistically. In the control group administered orally 
with the vehicle only, the tumor grew continuously to ca. 360 ± 20 mm3 in 45 days.  
4. Discussion 
In current study, we prepared oil formulations for oral administration of paclitaxel and 
examined their physical properties, pharmacokinetic profiles and antitumor activities.  
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Fig. 5. Antitumor activity of DHP107 in male Balb/c athymic mice, subcutaneously injected 
with suspension of NCI-H358 cells (1.2×107 cells/mouse). A) The entire tumor tissue 
removed surgically after the experiment. B) The volume of tumor for the oral vehicle control 
(eG2, ), intravenous Taxol® (, 10mg/kg) and oral DHP107 (G2, , 50 mg/kg). 
Paclitaxel was commercially available in at least two different polymorphs. Amorphous 
paclitaxel was readily soluble in our oral formulations at 10 mg/ml when sonicated for 30 s. 
Crystalline paclitaxel, on the other hand, did not dissolve in the oily formulations directly. We 
had to dissolve crystalline paclitaxel in the tricaprylin/methylene chloride mixture completely, 
and to remove the solvent in turn to obtain the oily solution of paclitaxel/tricaprylin before 
adding monoolein and Tween 80. Even though paclitaxel could also be dissolved in methylene 
chloride/tricaprylin/monoolein/Tween 80 as well as in methylene chloride/tricaprylin, 
monoolein and Tween 80 were not added to the mixture until after evaporating the solvent to 
minimize the oxidation of these materials containing unsaturated hydrocarbons. 
Pharmacokinetic study showed that AUC values were identical statistically when paclitaxel 
from different vendors or different preparation processes was used (Figure 4F). 
DSC study was performed for the formulations with different triglycerides. In the heating 
thermograms, two endothermic transitions were observed corresponding to the chain 
melting transitions of monoolein and triglycerides for T8 and T12 formulations. Chain 
melting transition of triacetin, tributyrin and tricaproin were not observed since the phase 
transition temperatures of these triglycerides were below 0 ˚C. There was only a single 
endothermic transition for the tricaprin/monoolein mixture at the weight ratio of 2:1 since 
www.intechopen.com
 
New Advances in the Basic and Clinical Gastroenterology 
 
370 
they formed a eutectic mixture (Roh et al., 2004). The phase behavior of monoolein and 
triglycerides could be explained by the classical binary eutectic phase diagram of two 
immiscible solid phases and a completely miscible melt.  
We could conclude from the DSC data that monoolein and tricaprylin do not mix below ca. 30 
˚C where monoolein exists as lamellar crystalline phase. Monoolein and Tween 80 did not mix 
in this temperature range either. Above 30 ˚C, however, all three ingredients, tricaprylin, 
monoolein and Tween 80 existed as liquid and mixed homogeneously. Two important things 
to note were that paclitaxel precipitates were not observed even at 0 ˚C by microscopy in any 
of the oral formulations and that the formulations could be heated and cooled in cycles 
between -20 and 40 ˚C without compromising the effectiveness of the drug. These results are 
significant in that the oral formulation (possibly in a soft capsule) can be stored in the shelf and 
orally administered in the phase-separated form, but transforms into a homogenous liquid 
solution by the body heat while traveling inside the gastrointestinal tract.  
In our oral formulations, monoolein was included due to its well-known mucoadhesive 
property (Nielsen et al., 1998). Monoolein and other monoglycerides have been used in oral 
drug delivery formulations since they can enhance absorption of small molecules and even 
proteins through the epithelial cells (Ganem-Quintanar et al., 2000; Chung et al., 2002). The 
absorption enhancing mechanism is not clearly known. Nanopore induction or the 
membrane perturbation (Anderson, 2005), and the intermediate phases formed in the 
intestine (Kossena et al., 2005) were considered important. In vitro study showed that 
monoglycerides can enhance the cellular absorption of drugs by inhibition of P-
glycoproteins (Konishi et al., 2004). Further studies are required to explain the absorption 
enhancing mechanism of monoolein unequivocally.  
In the previous study, we administered intravesically the dispersion of DHP107 in water to 
experimental rabbits and observed that the formulation adhered tightly to the bladder 
mucosa, and paclitaxel penetrated through the physical barrier imposed by the 
uroepithelium (S. J. Lee et al., 2005). Histological examination of the bladder and other 
tissues did not reveal any local or systemic toxicity to the rabbits.  
Oral administration of formulations containing different triglycerides showed that those with 
tricaproin, tricaprylin and tricaprin had higher AUC values than others. The formulation with 
tricaproin had the highest AUC value. We must note that paclitaxel was mixed directly with 
the vehicles and sonicated for 30 s to obtain the formulations in Table 2. When the preparation 
process was changed to add and to remove methylene chloride in turn in order to solubilize 
crystalline as well as amorphous paclitaxel, the AUC value of tricaprylin/monoolein/Tween 
80/paclitaxel formulation (G2, DHP107) increased from 8.9 to 11.0 μg·h/ml, which was similar 
to that of tricaproin/monoolein/Tween 80/paclitaxel formulation in Table 2 (T6) statistically. 
We proceeded with the tricaprylin/monoolein/Tween 80/paclitaxel formulation for further 
experiments because the toxicity of tricaprylin (LD50 = 3700 mg/kg; intravenous and 26600 
mg/kg; oral) was much lower than that of tricaproin (LD50 = 122 mg/kg; intravenous) for 
mice according to the Material Safety Data Sheets for tricaprylin (T9126) and tricaproin (T4137) 
provided by Sigma (www.sigma-aldrich.com).  
We also performed the pharmacokinetic study with the formulations having different 
contents of the drug, under fasting or non-fasting conditions, by changing the commercial 
source of paclitaxel, with or without the emulsifier, Tween 80 and in the form of dispersions 
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in syrup or in water. From these experiments, we could conclude that the optimum 
concentration of paclitaxel in the formulation was 10 mg/ml, and the 
tricaprylin/monoolein/Tween 80/paclitaxel formulation was the most effective when given 
directly to the non-fasting animals. Under the fasting conditions, Tmax was 3 h. Tmax, 
however, was 1 h when the animal had free access to food and water. In a separate 
experiment, we observed that the bile salts helped the micronization and micellization of 
DHP107. It is possible that the micronization process of DHP107 was fastened by the 
secreted bile salts already existing under the non-fasting condition. When the formulation 
was fed to the empty stomach, on the other hand, bile salt secretion would start after the oily 
DHP107 reaches the upper intestine.  
Our liquid type formulations were very effective in delivering paclitaxel orally, easy to 
prepare, biocompatible, and physically stable. Preclinical studies have demonstrated superior 
antitumor efficacy and high bioavailability. Most notably, the blood paclitaxel concentration 
was high after the oral administration even though the P-glycoprotein inhibitors were not co-
administered when compared to the formulations reported in the literature (Table 1). The 
results show that the blood paclitaxel concentration reached as high as ca. 3 μg/ml and higher 
than 1 μg/ml for 4~6 hours in Balb/c mice after oral administration of 50 mg/kg of paclitaxel 
dose. Also the bioavailability of paclitaxel was ca. 14 % and 20 % when compared to Taxol® 
injection under fasting and non-fasting conditions, respectively.  
Antitumor experiment also showed that the tumor regression rate of the oral DHP107 group 
(50 mg/kg) was similar to that of the intravenous Taxol® group (10 mg/kg). Also, the tumor 
size of an established non-small cell lung cancer was significantly reduced after the oral 
treatment. Considering that the bioavailability of DHP107 was ca. 14 ~ 20 % compared to 
Taxol® injection, similar regression rate was expected to a degree.  
5. Conclusions 
In conclusion, we prepared oral paclitaxel formulations that do not contain P-glycoprotein 
inhibitors as active pharmaceutical ingredients. The formulations are liquid at body 
temperature and can solubilize paclitaxel effectively. The oral bioavailability of paclitaxel 
was 14 ~ 20 % when compared to the intravenous Taxol® formulation without concomitant 
administration of P-glycoprotein inhibitors. Preclinical efficacy study on mice showed that 
the tumor size was reduced significantly for the human non-small cell lung carcinoma. In 
separate studies, we have determined the tissue distribution of paclitaxel after oral 
administration (manuscript in preparation) and performed pre-clinical antitumor efficacy 
studies in mice with several tumor types (manuscript in preparation). Regulatory preclinical 
experiments to initiate the clinical evaluations of DHP107 have also been carried out. 
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